Top-News

United Community Banks Aktie News

Aktie
WKN:  A1JB5Q ISIN:  US90984P3038 US-Symbol:  UCB Land:  USA
31,11 $
-0,25 $
-0,80%
26,718 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
16,47%
KGV
14,36
Dividende
0,25 $
Dividendenrendite
0,80%
Index-Zuordnung
-

United Community Banks News

03.04.25 - PR Newswire
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025
UCB presents latest research across leading neurology portfolio at American Academy of Neurology (AAN) meeting 2025 PR Newswire
27.03.25 - PR Newswire
United Community earns 11th J.D. Power Award in the last 16 years, Ranking #1 for Retail Banking Customer Satisfaction in the Southeast, plus #1 in Trust and People
United Community earns 11th J.D. Power Award in the last 16 years, Ranking #1 for Retail Banking Customer Satisfaction in the Southeast, plus #1 in Trust and People PR Newswire
19.03.25 - PR Newswire
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference
New data on investigational therapy for thymidine kinase 2 deficiency presented at Muscular Dystrophy Association (MDA) 2025 Conference PR Newswire
12.03.25 - PR Newswire
Epilepsia Publishes Final Analysis of Open-Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome
Epilepsia Publishes Final Analysis of Open-​Label Extension Study of Long-Term Safety and Effectiveness of FINTEPLA® (fenfluramine) in Children and Adults with Dravet Syndrome ...
07.03.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-to-Severe Plaque Psoriasis
BIMZELX® (bimekizumab-​bkzx) Five-Year Data at AAD 2025 Showed Sustained Skin Clearance and Long-Term Efficacy in Moderate-​to-Severe Plaque Psoriasis PR Newswire
07.03.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden
BIMZELX® (bimekizumab-​bkzx) Two-Year Data at AAD Showed Potential to Eliminate Draining Tunnels in Hidradenitis Suppurativa, and Reduction in Disease Burden PR Newswire
27.02.25 - PR Newswire
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth
On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth PR Newswire
26.02.25 - PR Newswire
United Community earns Coalition Greenwich Best Bank awards for Middle Market and Small Business Banking
United Community earns Coalition Greenwich Best Bank awards for Middle Market and Small Business Banking PR Newswire
16.01.25 - PR Newswire
UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)
UCB Announces U.S. Availability of 320 mg/2 mL Single-​Injection Administration Option for BIMZELX® (bimekizumab-​bkzx) PR Newswire
06.12.24 - PR Newswire
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting
UCB Presents New Data on Impact and Burden of Epilepsy at 2024 American Epilepsy Society (AES) Annual Meeting PR Newswire

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »